A critical appraisal of integrating family constellation therapy with pharmacological treatment for depression

Abstract

Depression remains a leading cause of disability worldwide, driven by a complex interplay of biological, psychological, and social factors. While pharmacotherapy, particularly selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, provides essential symptom control, its limitations—including delayed onset, variable response, and side effects—underscore the need for complementary approaches that address systemic and relational roots of the disorder. This narrative review synthesizes evidence on the integration of antidepressant medication with family constellation therapy (FCT), a systemic, experiential group intervention targeting transgenerational family dynamics. We first outline the core mechanisms and clinical challenges of pharmacotherapy, then examine how adverse family environments, dysfunctional communication patterns, and unresolved familial trauma contribute to depression risk. Next, we present the theoretical foundations and preliminary evidence base for FCT, noting moderate effect sizes for general psychopathology but a critical lack of depression-specific randomized trials. The central argument is that combining pharmacotherapy and FCT aligns with the biopsychosocial model by concurrently stabilizing acute biological symptoms and addressing the family-systemic factors that sustain vulnerability. However, direct comparative evidence is absent, and current support for integration is drawn largely from indirect data on combined psychotherapy and medication. We discuss sequential and parallel implementation models, highlight the urgent need for rigorous randomized controlled trials, and identify practical barriers including limited therapist training and the absence of standardized treatment protocols. In conclusion, the integration of pharmacotherapy with FCT represents a theoretically promising but empirically unvalidated strategy; its clinical utility will depend on the development of testable, manualized protocols and